非小细胞肺癌新辅助帕博利珠单抗后肺切除术的围术期结局
这项2期研究(NCT02818920)评估可切除非小细胞肺癌患者新辅助帕博利珠单抗后手术的安全性。35例入组,30例接受新辅助治疗,25例接受肺切除;仅1例因甲状腺炎延迟手术,无90天死亡,主要病理缓解7/25(28%),房颤最常见(6/25,24%)。
要点
- 新辅助帕博利珠单抗未增加手术死亡率或主要并发症。
- 25例中23例初始微创,5例中转开胸(21.7%)。
- 主要病理缓解率28%,高于标准化疗历史数据。
核心结论
- 新辅助帕博利珠单抗安全耐受,未增加手术并发症或死亡。
- 微创手术可行但可能较未接受免疫治疗者更具挑战。
- 病理缓解率高于标准化疗通常观察到的水平。
研究设计与样本
- 2期研究(NCT02818920),入组未经治疗临床IB-IIIA期非小细胞肺癌患者。
- 术前给予2周期帕博利珠单抗200 mg,术后提供4周期辅助帕博利珠单抗。
- 35例入组,30例接受新辅助治疗,25例接受肺切除。
主要发现
- 仅1例因帕博利珠单抗相关甲状腺炎延迟手术。
- 25例均行解剖性切除和纵隔淋巴结清扫,18例(72%)行肺叶切除。
- 23例(92%)初始微创,5例(21.7%)中转开胸。
- R0切除22例(88%),主要病理缓解7/25(28%)。
- 最常见术后不良事件为房颤(6/25,24%),中位胸管留置3天、住院4天,1例30天内再入院,无90天死亡。
关键数值与推荐
- 主要病理缓解定义为7/25(28%)。
- R0切除率为22/25(88%)。
- 微创初始比例23/25(92%),中转开胸率5/23(21.7%)。
- 房颤发生率6/25(24%)。
- 中位胸管留置3天,中位住院4天。
临床怎么用
- 新辅助帕博利珠单抗后肺切除安全可行,不增加围术期风险。
- 微创手术可尝试,但需警惕中转开胸可能。
- 术后房颤常见,应加强监测和管理。
局限性
- 单臂2期研究,样本量小(25例手术),无对照组。
- 主要终点为安全性,疗效为次要终点。
- 微创挑战性基于观察,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pembrolizumab is a programmed death receptor-1 masking antibody approved for metastatic non-small cell lung cancer. This Phase 2 study (NCT02818920) of neoadjuvant pembrolizumab in non-small cell lung cancer had a primary end point of safety and secondary end points of efficacy and correlative science. METHODS: Patients with untreated clinical stage IB to IIIA non-small cell lung cancer were enrolled. Two cycles of pembrolizumab (200 mg) were administered before surgery. Standard adjuvant chemotherapy and radiation were encouraged but not required. Four cycles of adjuvant pembrolizumab were provided. RESULTS: Of 35 patients enrolled, 30 received neoadjuvant pembrolizumab and 25 underwent lung resection. Only 1 patient had a delay before surgery attributed to pembrolizumab; this was due to thyroiditis. All patients underwent anatomic resection and mediastinal lymph node dissection; the majority (18/25%, 72%) of patients underwent lobectomy. Of the 25 patients, 23 had an initial minimally invasive approach (92%); 5 of these were converted to thoracotomy (21.7%). R0 resection was achieved in 22 patients (88%), and major pathologic response was observed in 7 of 25 patients (28%). The most common postoperative adverse event was atrial fibrillation, affecting 6 of 25 patients (24%). Median chest tube duration and length of stay were 3 and 4 days, respectively. One patient required readmission to the hospital within 30 days. There was no mortality within 90 days of surgery. CONCLUSIONS: In this study, pembrolizumab was safe and well tolerated in the neoadjuvant setting, and its use was not associated with excess surgical morbidity or mortality. Minimally invasive approaches are feasible in this patient population, but may be more challenging than in cases without neoadjuvant immunotherapy. Pathologic response was higher than typically observed with standard neoadjuvant chemotherapy.
引用
- Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021. PMID: 33985811. doi:10.1016/j.jtcvs.2021.02.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。